Abstract
Acute respiratory distress syndrome (ARDS) is a syndrome of acute respiratory failure
caused by noncardiogenic pulmonary edema. Despite five decades of basic and clinical
research, there is still no effective pharmacotherapy for this condition and the treatment
remains primarily supportive. It is critical to study the molecular and physiologic
mechanisms that cause ARDS to improve our understanding of this syndrome and reduce
mortality. The goal of this review is to describe our current understanding of the
pathogenesis and pathophysiology of ARDS. First, we will describe how pulmonary edema
fluid accumulates in ARDS due to lung inflammation and increased alveolar endothelial
and epithelial permeabilities. Next, we will review how pulmonary edema fluid is normally
cleared in the uninjured lung, and describe how these pathways are disrupted in ARDS.
Finally, we will explain how clinical trials and preclinical studies of novel therapeutic
agents have further refined our understanding of this condition, highlighting, in
particular, the study of mesenchymal stromal cells in the treatment of ARDS.
Keywords
acute respiratory distress syndrome - alveolar fluid clearance - vectorial ion transport
- pulmonary edema - mesenchymal stromal cells